|
KMID : 1040420230270020121
|
|
Childhood Kidney Diseases
2023 Volume.27 No. 2 p.121 ~ p.126
|
|
|
Angiotensin receptor blocker induced fetopathy: two case reports and literature review
|
|
Joung Jin-Woon
Cho Hee-Yeon
|
|
|
Abstract
|
|
|
|
The administration of angiotensin type 2 receptor blockers (ARBs) during pregnancy is known to cause ARB fetopathy, including renal insufficiency. We aimed to analyze the outcomes of two patients who survived ARB fetopathy and perform an accompanying literature review. Case 1 was exposed antenatally from a gestational age of 30 weeks to valsartan because of maternal pregnancy-induced hypertension. The patient presented with oliguria immediately after birth, and renal replacement therapy was administered for 24 days. Seven years after birth, renal function was indicative of stage 2 chronic kidney disease (CKD) with impaired urinary concentration. Case 2 had a maternal history of hypertension and transient ischemic attack and was treated with olmesartan until 30 weeks of pregnancy. Renal replacement therapy was performed for 4 days since birth. After 8 years, the patient is with CKD stage 2, with intact tubular function. Recent reports suggest that ARB fetopathy might manifest as renal tubular dysgenesis and nephrogenic diabetes insipidus, in contrast to mild alterations of glomerular filtration. Tubular dysfunction may induce CKD progression and growth retardation. Patients with ARB fetopathy should be monitored until adulthood. The ARB exposure period might be a critical factor in determining the severity and manifestations of fetopathy.
|
|
|
KEYWORD
|
|
|
Angiotensin-converting enzyme inhibitors, Angiotensin receptor antagonists, Case reports, Diabetes insipidus, nephrogenic, Renal insufficiency, chronic
|
|
|
FullTexts / Linksout information
|
|
|
|
|
|
Listed journal information
|
|
|
|